Abstract
Matriptase is an epithelial-derived, cell surface serine protease. This protease activates hepatocyte growth factor (HGF) and urokinase plasminogen activator (uPA), two proteins thought to be involved in the growth and motility of cancer cells, particularly carcinomas, and in the vascularization of tumors. Thus, matriptase may play an important role in the progression of carcinomas, such as breast cancer. We examined the regulation of activation of matriptase in human breast cancer cells, in comparison to non-transformed mammary epithelial cells 184A1N4 and MCF-10A. Results clearly indicated that unlike non-transformed mammary epithelial cells, breast cancer cells do not respond to the known activators of matriptase, serum and sphingosine 1-phosphate (S1P). Similar levels of activated matriptase were detected in breast cancer cells, grown in the presence or absence of S1P. However, up to five-fold higher levels of activated matriptase were detected in the conditioned media from the cancer cells grown in the absence of serum and S1P, when compared to non-transformed mammary epithelial cells. S1P also induces formation of cortical actin structures in non-transformed cells, but not in breast cancer cells. These results show that in non-transformed cells, S1P induces a rearrangement of the actin cytoskeleton and stimulates proteolytic activity on cell surfaces. In contrast, S1P treatment of breast cancer cells does not activate matriptase, and instead these cells constitutively activate the protease. In addition, breast cancer cells respond differently to S1P in terms of the regulation of actin cytoskeletal structures. Matriptase and its cognate inhibitor, HGF activator inhibitor 1 (HAI-1) colocalize on the cell periphery of breast cancer cells and form stable complexes in the extracellular milieu, suggesting that the inhibitor serves to prevent undesired proteolysis in these cells. Finally, we demonstrate that treatment of T-47D cells with epidermal growth factor (EGF), which promotes cell ruffling, stimulates increased accumulation of activated matriptase at the sites of membrane ruffling, suggesting a possible functional role at these sites.
Similar content being viewed by others
References
Lin CY, Anders J, Johnson M et al. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999; 274: 18231–6.
Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 1999; 96: 11054–61.
Tanimoto H, Underwood LJ, Wang Y et al. Ovarian tumor cells express a transmembrane serine protease: A potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 2001; 22: 104–14.
Kim MG, Chen C, Lyu MS et al. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 1999; 49: 420–8.
Hooper JD, Clements JA, Quigley JP et al. Type II transmembrane serine proteases, Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001; 276: 857–60.
Oberst M, Anders J, Xie B et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001; 158: 1301–11.
Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720–5.
Takeuchi T, Harris JL, Huang W et al. Cellular localization of membrane-type serine protease 1 and identification of protease activated receptor-2 and single-chain urokinase-type plasiminigen activator as substrates. J Biol Chem 2000; 275: 26333–42.
Benaud C, Dickson RB, Lin CY. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem 2001; 268: 1439–47.
Benaud C, Oberst M, Hobson JP et al. Sphingosine-1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem 2002; 277: 10539–46.
Lin CY, Wang JK, Torri J et al. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. J Biol Chem 1997; 272: 9147–52.
Lin CY, Anders J, Johnson M et al. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18237–42.
Shi YE, Torri J, Yieh L et al. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 1993; 53: 1409–15.
Shimomura T, Denda K, Kitamura A et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 6370–6.
Kawaguchi T, Qin L, Shimomura T et al. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 27558–64.
Wells A. Tumor invasion: Role of growth factor-induced cell motility. Adv Cancer Res 2000; 78: 31–101.
Xing RH, Rabbani SA. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer 1996; 67: 423–9.
Holst-Hansen C, Johannessen B, Hoyer-Hansen G et al. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996; 14: 297–307.
Tsunezuka Y, Kinoh H, Takino T et al. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 1996; 56: 5678–83.
Powell WC, Knox JD, Navre M et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993; 53: 417–22.
Look MP, Foekens JA. Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS 1999; 107: 150–9.
Barsky SH, Siegal GP, Jannotta F et al. Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 1983; 49: 140–7.
De Clerck YA, Perez N, Shimada H, Boone TC et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701–8.
Imren S, Kohn DB, Shimada H, Blavier L et al. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996; 56: 2891–5.
Albini A, Melchiori A, Santi L et al. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83: 775–9.
Khokha R, Zimmer MJ, Graham CH et al. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 1992; 84: 1017–22.
Lee MJ, Thangada S, Claffey KP et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99: 301–12.
Takaishi K, Sasaki T, Kotani H et al. Regulation of cell-cell adhesion by rac and rho small G proteins in MDCK cells. J Cell Biol 1997; 139: 1047–59.
Braga VM, Machesky LM, Hall A et al. The small GTPase Rho and Rac are required for the establishment of eadherin-dependent cell-cell contacts. J Cell Biol 1997; 137: 1421–31.
Sahai E, Marshall CJ. Rho-GTPase and Cancer. Nature Rev Cancer 2002; 2: 133–42.
Wang F, Van Brocklyn JR, Edsall L et al. Sphingosine-1-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors. Cancer Res 1999; 59: 6185–91.
Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999; 81: 682–7.
van Golen KL, Wu ZF, Qiao XT et al. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000; 2: 418–25.
Laug WE, Cao XR, Yu YB et al. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993; 53: 6051–7.
Menendez-Arias L, Risco C, Oroszlan S et al. Isolation and characterization of alpha 2-macroglobulin-protease complexes from purified mouse mammary tumor virus and culture supernatants from virus-infected cell lines. J Biol Chem 1992; 267: 11392–8.
Soff GA, Sanderowitz J, Gately S et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96: 2593–600.
Wang M, Liu YE, Greene J et al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997; 14: 2767–74.
Knoop A, Andreasen PA, Andersen JA et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77: 932–40.
Foekens JA, Peters HA, Look MP et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636–43.
Foekens JA, Schmitt M, van Putten WL et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648–58.
McCarthy K, Maguire T, McGreal G et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999; 84: 44–8.
Remacle A, McCarthy K, Noel A et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000; 89: 118–21.
Bajou K, Noel A, Gerard RD et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923–8.
Kataoka H, Shimomura T, Kawaguchi T et al. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000; 275: 40453–62.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Benaud, C.M., Oberst, M., Dickson, R.B. et al. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 19, 639–649 (2002). https://doi.org/10.1023/A:1020985632550
Issue Date:
DOI: https://doi.org/10.1023/A:1020985632550